Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance

作者:Isabelle Malet, Francesca Alessandra Ambrosio, Frédéric Subra, Béatrice Herrmann, Hervé Leh, Marie-Christine Bouger, Anna Artese, Christine Katlama, Carmine Talarico, Isabella Romeo, Stefano Alcaro, Giosuè Costa, Eric Deprez, Vincent Cálvez, Anne‐Geneviève Marcelin, Olivier Delelis · 发表于:Journal of Antimicrobial Chemotherapy · 年份:2017 · 被引用次数:20 · 研究领域:HIV/AIDS drug development and treatment、Biochemical and Molecular Research、Pharmacogenetics and Drug Metabolism

Background: Dolutegravir, an integrase strand-transfer inhibitor (STI), shows a high genetic barrier to resistance. Dolutegravir is reported to be effective against viruses resistant to raltegravir and elvitegravir. In this study, we report the case of a patient treated with dolutegravir monotherapy. Failure of dolutegravir treatment was observed concomitant with the appearance of N155H-K211R-E212T mutations in the integrase (IN) gene in addition to the polymorphic K156N mutation that was present at baseline in this patient. Methods: The impact of N155H-K156N-K211R-E212T mutations was studied in cell-free, culture-based assays and by molecular modelling. Results: Cell-free and culture-based assays confirm that selected mutations in the patient, in the context of the polymorphic mutation K156N present at the baseline, lead to high resistance to dolutegravir requiring that the analysis be done at timepoints longer than usual to properly reveal the results. Interestingly, the association of only N155H and K156N is sufficient for significant resistance to dolutegravir. Modelling studies showed that dolutegravir is less stable in IN/DNA complexes with respect to the WT sequence. Conclusions: Our results indicate that the stability of STI IN/DNA complexes is an important parameter that must be taken into account when evaluating dolutegravir resistance. This study confirms that a pathway including N155H can be selected in patients treated with dolutegravir with the help of the polym...